⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Suven Life Sciences Limited (SUVEN) — FY26 Annual Report | 30 July 2026(2 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
1 Annual Report 🔴 High Importance Neutral 📄 PDF
📢 Key Event
Annual Report FY2025-26 made available online for shareholders
💡 Investor Takeaway
Shareholders must update KYC details to receive dividends and access reports.

Suven Life Sciences disclosed that its FY2025-26 Annual Report is accessible via its website at https://www.suven.com/annualreports.aspx, urging shareholders to update PAN, KYC, and nomination details to ensure dividend payments and compliance, while highlighting a senior citizen investor cell for grievance redressal.

2 Annual Report 🔴 High Importance Neutral 📄 PDF
📢 Key Event
37th AGM approved financial statements, reappointed directors, approved related party transaction, and authorised variation in preferential issue fund utilisation.
🔄 What Changed
Reappointment of Dr. Vajja Sambasiva Rao as Independent Director for a second term and approval of Dr. Madhavi Jasti's appointment with USD 400,000 remuneration (capped at USD 1 million) as a material related party transaction.
🔮 What's Next
The company plans to reallocate unutilised preferential issue proceeds from CAPEX to clinical development and general corporate purposes, with continued monitoring by CRISIL as the appointed Monitoring Agency.
💡 Investor Takeaway
Shareholders approved key governance appointments and capital allocation adjustments, reflecting strategic focus on clinical development and capital efficiency.

Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026 via video conference, approving the adoption of FY2025-26 audited financial statements, reappointing Prof. Seyed E Hasnain as Director and Dr. Vajja Sambasiva Rao as Independent Director, approving Dr. Madhavi Jasti's appointment as a high-paid executive in overseas subsidiaries with USD 400,000 initial remuneration (capped at USD 1 million), and authorising variation in utilisation of preferential issue proceeds by reallocating unutilised funds from CAPEX to clinical development and general corporate purposes.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →
📊 Stock Analysis — SUVEN ✨ Ask AI About This

About Suven Life Sciences Limited (SUVEN)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹11,087.76 Cr ROE: -80.9% ROCE: -80.7%

View full SUVEN stock details →

📡 Get AI alerts when SUVEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUVEN — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More SUVEN filings

See all SUVEN filings →

🔥 Also filed on 30 July 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUVEN files new disclosures

Track SUVEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUVEN — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd